HeartWare International Q4 net loss decreases
Mar 11, 2013 (Datamonitor via COMTEX) --
HeartWare International, Inc., a provider of small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure, has reported that net loss for the fourth quarter ended December 31, 2012 was $21.10 million, or $1.46 loss per share, compared to a net loss of $21.56 million, or $1.53 loss per share, for the same quarter ended December 31, 2011.
Net revenues for the fourth quarter of 2012 were $32.66 million, compared to $23.06 million for the same quarter of 2011.
Net loss for the year ended December 31, 2012 was $87.72 million, or $6.15 loss per share, compared to a net loss of $55.05 million, or $3.94 loss per share, for the year ended December 31, 2011.
Net revenues for the year ended December 31, 2012 were $110.92 million, compared to $82.76 million for the year ended December 31, 2011.
"Our results for the fourth quarter reflect positive initial trends in the commercial launch of the HeartWare Ventricular Assist System in the US, following approval from the Food and Drug Administration (FDA) on November 20, 2012, and continued strong support from our international customers," explained Doug Godshall, President and CEO. "Today, more than 3,000 advanced heart failure patients globally have received the HeartWare System."
"With 345 HVAD pumps sold during the fourth quarter, the largest number in any quarter to date, the total number of pumps sold in 2012 was 1,217, compared to 932 pumps sold in 2011," added Mr Godshall. "Our team has been working diligently to expedite the training of additional hospitals in the US, and since FDA approval 18 new US sites have been trained, with 2 more in training this week."
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
[ Back To Technology News's Homepage ]